Bausch Health Companies Inc. /
DURECT Corporation
Bausch Health adds DURECT to its hepatology pipeline




Source for the buyer and target: Bausch Health Companies Inc.
For the buyer and target.
“LAVAL, QC, and CUPERTINO, CA, September 11, 2025 – Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (“Bausch Health”), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire DURECT Corporation (“DURECT”).”
Published 11 Sep 2025
Open the sourceWhat happened
Bausch Health Companies Inc. completed its acquisition of DURECT Corporation, adding larsucosterol to its hepatology pipeline. [01]
The deal included an upfront cash payment of approximately $63 million at closing, with potential additional net sales milestone payments of up to $350 million in the aggregate. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Bausch Health adds DURECT to its hepatology pipeline
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly